Who are Ivermectin and Doxycycline's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivermectin-and-doxycycline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ivermectin and Doxycycline — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivermectin and Doxycycline (Ivermectin and Doxycycline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic and antibiotic combination. Area: Infectious Disease.

phase 3 Antiparasitic and antibiotic combination GABA-gated chloride channels (ivermectin); bacterial 30S ribosome (doxycycline) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ivermectin and Doxycycline (Ivermectin and Doxycycline) — Bangladesh Medical Research Council (BMRC). Ivermectin paralyzes parasites by enhancing GABA-gated chloride channel activity, while doxycycline inhibits bacterial protein synthesis; together they target parasitic and bacterial co-infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ivermectin and Doxycycline TARGET	Ivermectin and Doxycycline	Bangladesh Medical Research Council (BMRC)	phase 3	Antiparasitic and antibiotic combination	GABA-gated chloride channels (ivermectin); bacterial 30S ribosome (doxycycline)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic and antibiotic combination class)

Bangladesh Medical Research Council (BMRC) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ivermectin and Doxycycline — Competitive Intelligence Brief. https://druglandscape.com/ci/ivermectin-and-doxycycline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing